New metal-based nanoparticles for intravenous use: Requirements for clinical success with focus on medical imaging

Nanomedicine: Nanotechnology, Biology, and Medicine

Volumn 6, Issue 6, 2010, Pages 730-737

  Skotland, Tore ^a,b   Iversen, Tore Geir ^a,b   Sandvig, Kirsten ^a,b  

^a UNIVERSITY OF OSLO   (Norway)

^b OSLO UNIVERSITY HOSPITAL   (Norway)

Author keywords

Excretion; Imaging; Intravenous injection; Metabolism; Metal based nanoparticles

Indexed keywords

ANIMAL STUDIES; BIODISTRIBUTIONS; BIOLOGICAL PROCESS; CLINICAL IMAGING; CRITICAL PARAMETER; EXCRETION; HYDRODYNAMIC DIAMETER; IMAGING; IMAGING AGENT; IN-VIVO IMAGING; INTRAVENOUS INJECTIONS; IRON OXIDE PARTICLES; LOW BACKGROUND; MEDICAL USE; PLASMA PROTEIN;

BLOOD; IRON OXIDES; METABOLISM; METALS; NANOPARTICLES; PHYSIOLOGY;

MEDICAL IMAGING;

IRON OXIDE; METAL COMPLEX; NANOPARTICLE; PLASMA PROTEIN; QUANTUM DOT; SUPERPARAMAGNETIC IRON OXIDE;

CLINICAL PRACTICE; COMPUTER ASSISTED TOMOGRAPHY; DIAGNOSTIC IMAGING; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG EXCRETION; DRUG SAFETY; HYDRODYNAMICS; IN VIVO STUDY; ISOTOPE LABELING; MOLECULAR IMAGING; NANOTECHNOLOGY; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PARTICLE SIZE; POSITRON EMISSION TOMOGRAPHY; REVIEW; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY;

ANIMALS; DIAGNOSTIC IMAGING; HUMANS; INJECTIONS, INTRAVENOUS; METAL NANOPARTICLES; NANOTECHNOLOGY;

ANIMALIA;

EID: 78649893671     PISSN: 15499634     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.nano.2010.05.002     Document Type: Review

References (65)

1. Hoffman J.M., Gambhir S.S. Molecular imaging: the vision and opportunity for radiology in the future. Radiology 2007, 244:39-47.
2. McCarthy J.R., Kelly K.A., Sun E.Y., Weissleder R. Targeted delivery of multifunctional magnetic nanoparticles. Nanomedicine (Lond.) 2007, 2:153-167.
3. Kaufmann B.A., Lindner J.R. Molecular imaging with targeted contrast ultrasound. Curr Opin Biotechnol 2007, 18:11-16.
4. Weissleder R., Pittet M.J. Imaging in the era of molecular oncology. Nature 2008, 452:580-589.
5. Wadsak W., Mitterhauser M. Basics and principles of radiopharmaceuticals for PET/CT. Eur J Radiol 2010, 73:461-469.
6. Massoud T.F., Gambhir S.S. Molecular imaging in living subjects: seeing fundamental biological processes in a new light. Genes Dev 2003, 17:545-580.
7. Corot C., Robert P., Idee J.M., Port M. Recent advances in iron oxide nanocrystal technology for medical imaging. Adv Drug Deliv Rev 2006, 58:1471-1504.
8. Gao X., Yang L., Petros J.A., Marshall F.F., Simons J.W., Nie S. In vivo molecular and cellular imaging with quantum dots. Curr Opin Biotechnol 2005, 16:63-72.
9. Jamieson T., Bakhshi R., Petrova D., Pocock R., Imani M., Seifalian A.M. Biological applications of quantum dots. Biomaterials 2007, 28:4717-4732.
10. Michalet X., Pinaud F.F., Bentolila L.A., Tsay J.M., Doose S., Li J.J., et al. Quantum dots for live cells, in vivo imaging, and diagnostics. Science 2005, 307:538-544.
11. Pan D., Lanza G.M., Wickline S.A., Caruthers S.D. Nanomedicine: perspective and promises with ligand-directed molecular imaging. Eur J Radiol 2009, 70:274-285.
12. 18F-labeled nanoparticles for in vivo PET-CT imaging. Bioconjug Chem 2009, 20:397-401.
13. Cormode D.P., Jarzyna P.A., Mulder W.J., Fayad Z.A. Modified natural nanoparticles as contrast agents for medical imaging. Adv Drug Deliv Rev 2010, 62:329-338.
14. 3+ doped fluoride nanophosphors. Nano Lett 2008, 8:3834-3838.
15. Li Z., Zhang Y., Shuter B., Muhammad I.N. Hybrid lanthanide nanoparticles with paramagnetic shell coated on upconversion fluorescent nanocrystals. Langmuir 2009, 25:12015-12018.
16. Burns A.A., Vider J., Ow H., Herz E., Penate-Medina O., Baumgart M., et al. Fluorescent silica nanoparticles with efficient urinary excretion for nanomedicine. Nano Lett 2009, 9:442-448.
17. Hainfeld J.F., Slatkin D.N., Focella T.M., Smilowitz H.M. Gold nanoparticles: a new X-ray contrast agent. Br J Radiol 2006, 79:248-253.
18. Patra C.R., bdel Moneim S.S., Wang E., Dutta S., Patra S., Eshed M., et al. In vivo toxicity studies of europium hydroxide nanorods in mice. Toxicol Appl Pharmacol 2009, 240:88-98.
19. Gilad A.A., Walczak P., McMahon M.T., Na H.B., Lee J.H., An K., et al. MR tracking of transplanted cells with ″ positive contrast″ using manganese oxide nanoparticles. Magn Reson Med 2008, 60:1-7.
20. Maysinger D., Lovric J., Eisenberg A., Savic R. Fate of micelles and quantum dots in cells. Eur J Pharm Biopharm 2007, 65:270-281.
21. Hild W.A., Breunig M., Goepferich A. Quantum dots-nano-sized probes for the exploration of cellular and intracellular targeting. Eur J Pharm Biopharm 2008, 68:153-168.
22. Zhang H., Yee D., Wang C. Quantum dots for cancer diagnosis and therapy: biological and clinical perspectives. Nanomedicine (Lond.) 2008, 3:83-91.
23. Juzenas P., Chen W., Sun Y.P., Coelho M.A., Generalov R., Generalova N., et al. Quantum dots and nanoparticles for photodynamic and radiation therapies of cancer. Adv Drug Deliv Rev 2008, 60:1600-1614.
24. Longmire M., Choyke P.L., Kobayashi H. Clearance properties of nano-sized particles and molecules as imaging agents: considerations and caveats. Nanomedicine (Lond.) 2008, 3:703-717.
25. Delehanty J.B., Mattoussi H., Medintz I.L. Delivering quantum dots into cells: strategies, progress and remaining issues. Anal Bioanal Chem 2009, 393:1091-1105.
26. Patra C.R., Bhattacharya R., Mukhopadhyay D., Mukherjee P. Fabrication of gold nanoparticles for targeted therapy in pancreatic cancer. Adv Drug Deliv Rev 2010, 62:346-361.
27. Gaumet M., Vargas A., Gurny R., Delie F. Nanoparticles for drug delivery: the need for precision in reporting particle size parameters. Eur J Pharm Biopharm 2008, 69:1-9.
28. Nel A., Xia T., Madler L., Li N. Toxic potential of materials at the nanolevel. Science 2006, 311:622-627.
29. Klaine S.J., Alvarez P.J., Batley G.E., Fernandes T.F., Handy R.D., Lyon D.Y., et al. Nanomaterials in the environment: behavior, fate, bioavailability, and effects. Environ Toxicol Chem 2008, 27:1825-1851.
30. Xia T., Li N., Nel A.E. Potential health impact of nanoparticles. Annu Rev Public Health 2009, 30:137-150.
31. Rzigalinski B.A., Strobl J.S. Cadmium-containing nanoparticles: perspectives on pharmacology and toxicology of quantum dots. Toxicol Appl Pharmacol 2009, 238:280-288.
32. Jones C.F., Grainger D.W. In vitro assessments of nanomaterial toxicity. Adv Drug Deliv Rev 2009, 61:438-456.
33. Derfus A.M., Chan W.C.W., Bhatia S.N. Probing the cytotoxicity of semiconductor quantum dots. Nano Lett 2004, 4:11-18.
34. Cho S.J., Maysinger D., Jain M., Roder B., Hackbarth S., Winnik F.M. Long-term exposure to CdTe quantum dots causes functional impairments in live cells. Langmuir 2007, 23:1974-1980.
35. Schneider G.F., Subr V., Ulbrich K., Decher G. Multifunctional cytotoxic stealth nanoparticles. A model approach with potential for cancer therapy. Nano Lett 2009, 9:636-642.
36. Choi H.S., Ipe B.I., Misra P., Lee J.H., Bawendi M.G., Frangioni J.V. Tissue- and organ-selective biodistribution of NIR fluorescent quantum dots. Nano Lett 2009, 9:2354-2359.
37. Schipper M.L., Iyer G., Koh A.L., Cheng Z., Ebenstein Y., Aharoni A., et al. Particle size, surface coating, and PEGylation influence the biodistribution of quantum dots in living mice. Small 2009, 5:126-134.
38. Aillon K.L., Xie Y., El-Gendy N., Berkland C.J., Forrest M.L. Effects of nanomaterial physicochemical properties on in vivo toxicity. Adv Drug Deliv Rev 2009, 61:457-466.
39. Hauck T.S., Anderson R.E., Fischer H.C., Newbigging S., Chan W.C.W In vivo quantum-dot toxicity assessment. Small 2010, 6:138-144.
40. Sonavane G., Tomoda K., Makino K. Biodistribution of colloidal gold nanoparticles after intravenous administration: effect of particle size. Colloids Surf B Biointerfaces 2008, 66:274-280.
41. De Jong W.H., Hagens W.I., Krystek P., Burger M.C., Sips A.J., Geertsma R.E. Particle size-dependent organ distribution of gold nanoparticles after intravenous administration. Biomaterials 2008, 29:1912-1919.
42. Braet F., Wisse E. Structural and functional aspects of liver sinusoidal endothelial cell fenestrae: a review. Comp Hepatol 2002, 1:1.
43. Jarad G., Miner J.H. Update on the glomerular filtration barrier. Curr Opin Nephrol. Hypertens 2009, 18:226-232.
44. Goldberg B.B., Merton D.A., Liu J.B., Murphy G., Forsberg F. Contrast-enhanced sonographic imaging of lymphatic channels and sentinel lymph nodes. J Ultrasound Med 2005, 24:953-965.
45. Hoshino A., Hanaki K., Suzuki K., Yamamoto K. Applications of T-lymphoma labeled with fluorescent quantum dots to cell tracing markers in mouse body. Biochem Biophys Res Commun 2004, 314:46-53.
46. Ballou B., Lagerholm B.C., Ernst L.A., Bruchez M.P., Waggoner A.S. Noninvasive imaging of quantum dots in mice. Bioconjug Chem 2004, 15:79-86.
47. Moestue S., Nunez P., Healey A., Bjerke R., Indrevoll B., Skotland T., et al. Whole-body section fluorescence imaging-a novel method for tissue distribution studies of fluorescent substances. Contrast Media Mol Imaging 2009, 4:73-80.
48. Yang R.S.H., Chang L.W., Wu J.P., Tsai M.H., Wang H.J., Kuo Y.C., et al. Persistent tissue kinetics and redistribution of nanoparticles, quantum dot 705, in mice: ICP-MS quantitative assessment. Environ Health Perspect 2007, 115:1339-1343.
49. Sadauskas E., Danscher G., Stoltenberg M., Vogel U., Larsen A., Wallin H. Protracted elimination of gold nanoparticles from mouse liver. Nanomed Nanotechnol Biol Med 2009, 5:162-169.
50. Steinman R.M., Mellman I.S., Muller W.A., Cohn Z.A. Endocytosis and the recycling of plasma membrane. J Cell Biol 1983, 96:1-27.
51. Choi H.S., Liu W., Misra P., Tanaka E., Zimmer J.P., Itty I.B., et al. Renal clearance of quantum dots. Nat Biotechnol 2007, 25:1165-1170.
52. Balogh L., Nigavekar S.S., Nair B.M., Lesniak W., Zhang C., Sung L.Y., et al. Significant effect of size on the in vivo biodistribution of gold composite nanodevices in mouse tumor models. Nanomed Nanotechnol Biol Med 2007, 3:281-296.
53. Schipper M.L., Cheng Z., Lee S.W., Bentolila L.A., Iyer G. Rao J, et al. microPET-based biodistribution of quantum dots in living mice. J Nucl Med 2007, 48:1511-1518.
54. Wang Y.X., Hussain S.M., Krestin G.P. Superparamagnetic iron oxide contrast agents: physicochemical characteristics and applications in MR imaging. Eur Radiol 2001, 11:2319-2331.
55. Rogers W.J., Meyer C.H., Kramer C.M. Technology insight: in vivo cell tracking by use of MRI. Nat Clin Pract Cardiovasc Med 2006, 3:554-562.
56. Skotland T., Sontum P.C., Oulie I. In vitro stability analyses as a model for metabolism of ferromagnetic particles (Clariscan), a contrast agent for magnetic resonance imaging. J Pharm Biomed Anal 2002, 28:323-329.
57. Trikha J., Waldo G.S., Lewandowski F.A., Ha Y., Theil E.C., Weber P.C., et al. Crystallization and structural analysis of bullfrog red cell L-subunit ferritins. Proteins 1994, 18:107-118.
58. Hardman R.A. A toxicological review of quantum dots: toxicity depends on physiochemical and environmental factors. Environ Health Perspect 2006, 114:165-172.
59. U.S.Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (CDER), Center for Biologics Evaluation and Research (CBER) Guidance for industry. Developing medical imaging drug and biological products. Part 1: Conducting safety assessments http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidance/ucm078930.pdf.
60. http://las.perkinelmer.com/Content/TechnicalInfo/TCH_ICPMSThirtyMinuteGuide.pdf.
61. Tysiak E., Asbach P., Aktas O., Waiczies H., Smyth M., Schnorr J., et al. Beyond blood brain barrier breakdown-in vivo detection of occult neuroinflammatory foci by magnetic nanoparticles in high field MRI. J Neuroinflammation 2009, 6:20.
62. Laurent S., Vander E.L., Muller R.N. Lanthanide complexes for magnetic resonance and optical molecular imaging. Q J Nucl Med Mol Imaging 2009, 53:586-603.
63. Rabin O., Manuel P.J., Grimm J., Wojtkiewicz G., Weissleder R. An X-ray computed tomography imaging agent based on long-circulating bismuth sulphide nanoparticles. Nat Mater 2006, 5:118-122.
64. Rofsky N.M., Sherry A.D., Lenkinski R.E. Nephrogenic systemic fibrosis: a chemical perspective. Radiology 2008, 247:608-612.
65. Zolnik B.S., Sadrieh N. Regulatory perspective on the importance of ADME assessment of nanoscale material containing drugs. Adv Drug Deliv Rev 2009, 61:422-427.